You just read:

FDA Approves Libtayo® (cemiplimab-rwlc) as First and Only Treatment for Advanced Cutaneous Squamous Cell Carcinoma

News provided by

Regeneron Pharmaceuticals, Inc.

Sep 28, 2018, 16:39 ET